Cipla Limited Share Price & Stock Analysis

Cipla Limited (NSE: CIPLA, BSE: 500087) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,14,712 Cr, it ranks #103 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,391.80 (as of 16 Nov 2026), the share price is 9.6% below its 52-week high of ₹1,539.70 and 19.4% above its 52-week low of ₹1,165.70. The share price is down 7.6% over one year and down 4.6% over three months.

Key Metrics

Current Price₹1,391.80
Market Cap₹1,14,712 Cr
NSE SymbolCIPLA
BSE Code500087
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio29.3
Return on Equity11.74%
Return on Assets7.58%
52-Week Range₹1,165.70 – ₹1,539.70
1-Year Price Change-7.6%
3-Month Price Change-4.6%
Beta (1Y)-0.02
Dividend Yield0.93%
HeadquartersMumbai, Maharashtra
Websitewww.cipla.com

Latest Quarterly Results — Q2 FY27

Revenue₹7,404 Cr
Net Profit₹852 Cr
Net Margin11.5%
EPS (Basic)₹10.86
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Cipla Limited Quarterly Revenue and Profit Trend

Cipla Limited reported revenue of ₹7,404 Cr in Q2 FY27, down 2.4% from ₹7,589 Cr in Q2 FY26 and up 4.0% from ₹7,119 Cr in Q1 FY27. It posted a net profit of ₹852 Cr for the quarter, against a net profit of ₹1,353 Cr in Q2 FY26 (down 37.1%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹6,541 Cr (Q4 FY26) to ₹7,589 Cr (Q2 FY26). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹7,404 Cr₹852 Cr11.5%
Q1 FY27₹7,119 Cr₹786 Cr11.0%
Q4 FY26₹6,541 Cr₹543 Cr8.3%
Q3 FY26₹7,074 Cr₹674 Cr9.5%
Q2 FY26₹7,589 Cr₹1,353 Cr17.8%
Q1 FY26₹6,957 Cr₹1,292 Cr18.6%
Q4 FY25₹6,730 Cr₹1,214 Cr18.0%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 29.21% of Cipla Limited's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 57.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Cipla Limited

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Products and Services

1. Pharmaceuticals-This segment develops, manufactures, sells, and distributes generic or branded generic medicines, as well as active pharmaceutical ingredients. 2. New Ventures-This segment engages in the consumer healthcare, biosimilars, and specialty businesses. 3. Inter Segment Revenue-0 4. Segment Adjustment-0

Business Segments

1. Pharmaceutical and Related Products-100%

Cipla Limited vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Glenmark Pharmaceuticals Limited₹75,556 Cr55.114.07%₹4,157 Cr+45.7%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Cipla Limited?

Cipla Limited is trading at ₹1,391.80, with a market capitalisation of ₹1,14,712 Cr.

Which sector does Cipla Limited belong to?

Cipla Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Cipla Limited?

Cipla Limited has a P/E of 29.3 and a return on equity of 11.74%.

What is the stock symbol of Cipla Limited?

Cipla Limited is listed on the NSE under the symbol CIPLA and on the BSE under the scrip code 500087.

How has Cipla Limited's share price moved over the past year?

Cipla Limited's share price is down 7.6% over one year and down 4.6% over three months. Its 52-week range is ₹1,165.70 to ₹1,539.70.

What were Cipla Limited's latest quarterly results?

In Q2 FY27, Cipla Limited reported revenue of ₹7,404 Cr and net profit of ₹852 Cr, with basic EPS of ₹10.86 (consolidated, parsed from the company's exchange filing).

How have Cipla Limited's revenue and profit changed over the past year?

Cipla Limited reported revenue of ₹7,404 Cr in Q2 FY27, down 2.4% from ₹7,589 Cr in Q2 FY26 and up 4.0% from ₹7,119 Cr in Q1 FY27.

What is the promoter holding in Cipla Limited?

Promoters held 29.21% of Cipla Limited's shares as of Sept 2026, unchanged from Sept 2025.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.